

GSK momentum continues with strong start to 2023

“We have made a strong start to 2023, with excellent performance across Vaccines, Specialty and General Medicines. We are now very focused on our upcoming launches, including for our potential RSV older adult vaccine, and on continuing to strengthen our pipeline – both organically with several positive late-stage read-outs already this year, and through targeted business development. Our continued momentum is also supporting our confidence in delivering our medium and long-term growth ambitions.”

Emma Walmsley
Chief Executive Officer, GSK



Vaccines

£ 2.0bn

+15%, +9%

including and excluding COVID-19 solutions

Specialty Medicines

£2.2bn

-33%, +13%

including and excluding COVID-19 solutions

General Medicines

£2.7bn

+9%

Adjusted Group operating margin

30.1%

Total EPS

36.8p

Adjusted EPS

37.0p

Dividend

14p

68

vaccines and specialty medicines in pipeline

17

pipeline assets in phase III / registration

Journalists/media see press release on www.gsk.com for full details on Q1 2023.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 44 to 46 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.